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Background: Focal cartilage injuries in the knee might have devastating effect due to the predisposition of early
onset osteoarthritis. Various surgical treatment options are available, however no statistically significant differences
have been found between the different surgical treatments. This supports the suggestion that the improvement
might be a result of the post-operative rehabilitation rather than the surgery itself. Autologous chondrocyte
implantation (ACI) has become a recognized treatment option for larger cartilage lesions in the knee. Although ACI
has been compared to other surgical treatment such as microfracture and mosaicplasty, it has never been directly
compared to simple arthroscopic debridement and rehabilitation alone. In this study we want to increase clinical
and economic knowledge about autologous chondrocyte implantation compared to arthroscopic debridement and
physical rehabilitation in the short and long run.
Methods/Design: We will conduct a randomized controlled trial to compare ACI with simple arthroscopic
debridement (AD) and physiotherapy for the treatment of cartilage lesions in the knee. The study will include a
total of 82 patients, both men and non-pregnant women, with a full thickness cartilage defect in the weight
bearing area of the femoral condyles or trochlea larger than 2 cm2. The lesion must be symptomatic, with a
Lysholm score less than 75.
The two treatment groups will receive identical rehabilitation protocol according to a modification of Wondrasch
et al., which is an active rehabilitation and education program divided into 3 phases: accommodation, rehabilitation
and return to activity. The patients will be followed for 24 months, with additional late follow-ups at 5 and 10 years
to monitor the potential onset of osteoarthtitis.
The primary outcome measure will be the difference in the KOOS knee-related quality of life (QoL) subscore in the
ACI group compared to the AD group at 2 years. A combination of self-explanatory questionnaires, clinical
parameters, clinical hop tests and radiographs and Magnetic Resonance Imaging (MRI) will be used as secondary
endpoints.
Discussion: This is the first study with a high level of evidence to compare ACI with simple debridement and
physiotherapy for the treatment of isolated symptomatic full thickness lesions of the knee.
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The articular surfaces of joints are covered with hyaline
cartilage, a unique tissue with extreme load shearing and
low-friction properties. However, these characteristics
come with a cost. It is aneural and avascular which ex-
plains its limited ability to self-repair [1–3]. Damage to
the cartilage, which is common in young active adults,
will therefore lead to permanent damage. These injuries
are very common, with a reported prevalence of 12 % in
the population [4]. Focal cartilage lesions predispose to
development of early onset osteoarthritis, which in turn
may lead to long rehabilitation periods and loss of func-
tion and time off work. Musculoskeletal problems are
one of the major reasons for workers compensation and
especially for younger patients this may lead to a signifi-
cant reduced quality of life and loss of income [5–8].
Treatment of symptomatic cartilage injuries in the knee
is therefore of particular interest and importance to the
patient, the surgeon and the society [1, 9, 10].
The ideal treatment for isolated cartilage injuries aims
at recreating a healthy hyaline-type tissue with similar
strength and durability as the normal cartilage in the
rest of the joint. Current surgical treatment options
include debridement, microfracture, autologous osteo-
chondral transplantation (mosaicplasty) and autologous
chondrocyte implantation (ACI) [11–13]. Several studies
conclude that microfracture is not effective for larger le-
sions [14, 15]. The purpose of arthroscopic debridement
is to remove loose intraarticular tissue debris and in-
flammatory mediators down to the subchondral bone,
but not through it [13]. ACI attempts to re-implant the
patient’s own chondrocytes over the defect to permit the
chondrocytes to heal back onto the bone and mature
into a hyaline-like cartilage. ACI have been directly com-
pared to microfracture and mosaicplasty in randomized
controlled trials [16–18]. The results indicate improved
knee function in (carefully selected) patients [19], but
studies have been criticized for methodological weak-
nesses [20]. The Cochrane database reported that there
is insufficient evidence to conclude that ACI is superior
to other treatment strategies for treating full thickness
cartilage defect of the knee [21].
No statistically significant differences have been found
between the different surgical treatments. This supports
the suggestion that the improvement might be a result
of the post-operative rehabilitation rather than the sur-
gery itself [22, 23]. Furthermore, inclusion in a clinical
trial is known to improve symptoms by itself, known as
the Hawthorne effect [24].
All studies on cartilage reconstructive surgery have
put the patients through a strict, careful, intensive and
prolonged rehabilitation following the procedure, which
could contribute to the clinical improvement observed.
Wondrasch and co-workers implemented an activerehabilitation program in 48 patients with focal cartilage
damage to a weight-bearing area of the knee [23]. None
of the patients had any form of surgery to their injury.
After three months there was a statistical significant and
clinical meaningful improvement in KOOS score, load
progression and hop score, to the point where 31 (65 %)
of the patients declined further surgery for their cartilage
lesion. This indicates that good results can be achieve
with physiotherapy alone. Dozin and coworkers com-
pared ACI versus mosaicplasty, where all candidates
where evaluated arthroscopically with debridement of
the lesion 6 months prior to definitive treatment [16].
All candidates completed an intensive rehabilitation
protocol following the debridement, but before the car-
tilage surgery. This included non-weight bearing for two
weeks and immediate active and passive physiotherapy.
After two weeks isometric and proprioception exercises
were introduced, as well as gradually strengthening exer-
cises. 31 % of the candidates experienced substantial
clinical improvement following the debridement and
physiotherapy alone, and needed no further (surgical)
treatment, questioning the need for cartilage treatment
as a first port of call in such patients. The authors con-
clude that further randomized clinical trials are needed,
where ACI should be compared to debridement alone.
This is a missing link in our knowledge of cartilage re-
constructive surgery and hampers further progression in
cell therapy [16, 25].
Purpose of this study
The purpose of this trial is to compare autologous chon-
drocyte implantation (ACI) with arthroscopic debride-
ment (AD) in symptomatic cartilage injuries larger than
2 cm2 in patients aged 18–50 years old in regard to both
subjective and objective variables at predefined times as
described under “variables” in section 6.
Methods/Design
The study is part of “The Norwegian Cartilage Project
(NCP): A multidisciplinary Approach to Improve the
Treatment of Injured Articular Cartilage”, which is a
total of five studies regarding cartilage injuries in the
knee, including clinical trials, register studies and basic
research studies.
This study is a prospective, randomized, controlled
study with 2 treatment arms (ACI and AD). Because one
treatment arm consists of a two stage surgery, with a
mini-open arthrotomy, while the other treatment arm is
a single stage arthroscopy, it will not be possible to blind
the patients as to what treatment they have received.
Inclusion and treatment will take place at Akershus
University Hospital (Ahus) or Oslo University Hospital
(Ullevål). The follow up appointments will be performed
at Ahus or at the local NCP affiliated hospital by an
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
-Age 18–50 years old -Osteoarthritis, rheumatoid or other
systemic arthritis
-Single symptomatic cartilage defect
on medial or lateral femoral condyle
or trochlea
-Malalignment >5° measured on
HKA images
-Defect size larger than 2 cm2 -No radiological osteoarthritis
-Lesion graded ICRS 3–4 -Obesity (Body mass index > 30)
- > 50 % intact meniscus -Comorbidities that may influence
surgery or rehabilitation
-Ligamentous stable knee -Pregnancy
-Acceptable range of motion (5–105°) -Inability to complete questionnaires
or rehabilitation
-Lysholm score < 75 -Serious alcohol or drug abuse
-Informed consent -Previous surgery to the chondral
defect except OCD surgery
Randsborg et al. BMC Musculoskeletal Disorders  (2016) 17:117 Page 3 of 9external reviewer connected to the NCP group. The fol-
low up will be blinded so that the examinator is unaware
of which treatment arm the patient belongs to. To
achieve this, the patient is instructed not to reveal the
nature of the treatment he/she has received, and an
opaque elastic stocking is put over the knee to conceal
the scars (which are different between the treatments).
Follow up is planned to 2 years, but each participant will
also be invited to clinical and radiological follow ups
after 5 and 10 years. The study has received ethical ap-
proval from the Regional Committee for Medical and
Health Research Ethics North-Norway (Approval num-
ber 2015/2200). Written informed consent will be ob-
tained from the subjects.
Participants
The study will include a total of 82 patients, both men
and non-pregnant women, with a full thickness or osteo-
chondral defect in the weight bearing area of the femoral
condyles or trochlea larger than 2 cm2. The lesion must
be symptomatic, with a Lysholm score less than 75 [26].
The inclusion criteria are based on the recommenda-
tions by Brittberg [27], and include patients aged 18 to
50 years old with a stable knee, good range of motion
(ROM), normal alignment (less than 5° varus or valgus
measured on hip-knee-ankle (HKA) angle images) and
no sign of radiologically osteoarthritis classified after
Kellgren-Lawrence [28]. The weight-bearing, fixed-flexion
posteroanterior radiographs will be obtained with the
SynaFlex X-ray positioning frame (Synarc) [29].
Inclusion
All patients will be assessed clinically as well as radio-
logically prior to inclusion to avoid peroperative exclu-
sions. The full thickness or osteochondral defect will be
verified arthroscopically as a grade 3 or 4 lesion accord-
ing to the International Cartilage Repair Society (ICRS)
[30]. Some patients might be excluded peroperatively
based on arthroscopic findings such as osteoarthritis,
less than 50 % normal meniscus or inappropriate size of
the lesion [31]. The definitive inclusion of the patient
will be performed by the operating surgeon during the
diagnostic arthroscopy, prior to randomization. Patients
who will be excluded based on peroperative findings will
receive appropriate treatment according to the standard
of care at the local hospitals.
Exclusion criteria include general osteoarthritis, sys-
temic arthritis, severe co-morbidities that may influence
surgery or rehabilitation potential, significant alcohol or
drug abuse, psychiatric disorders, language barriers,
pregnancy, severe obesity (body mass index > 30) and
previous surgery to the chondral defect such microfrac-
ture or mosaicplasty (previous cruciate ligament recon-
struction, fixation of osteochondritis dissecans lesions,alignment procedures (osteotomies) or meniscal surger-
ies are not exclusion criteria). Patients declining partici-
pation in the trial (and who fulfill the inclusion criteria)
or withdrawing underway will receive appropriate treat-
ment according to the standard of care at the local
hospital.
The inclusion and exclusion criteria are presented in
Table 1.Randomization
The randomisation will be performed using a computer
generator (randomization.org). 82 patient will be block ran-
domized in pairs of six-eight (1:1) to treatment allocations.
Each patient receives a patient number (1 through 82) on
inclusion. Randomization will be printed in faded text and
concealed in opaque numerically marked envelopes. The
printing and concealing will be done by a person working
at Akershus University Hospital, but is not involved in the
study, to secure blinding. The randomization process oc-
curs in the operation theatre during the arthroscopy after
the operating surgeon has measured and graded the lesion
to fulfill the inclusion criteria (see “Operative procedure”).Operative procedure
In this study Autologous Chondrocyte Implantation
(ACI) is compared with Arthroscopic Debridement
(AD). All patients will undergo a diagnostic arthroscopy,
and patients randomized to AD will have this procedure
performed at the end of the diagnostic arthroscopy,
while for the patients in the ACI group the chondrocyte
implantation will take place two weeks later in a second
stage operation as described below. The Study Flow
Chart is presented in Fig. 1. The ACI technique is based
on the technique described by Brittberg [32].
Fig. 1 Study flow chart
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Three standard incisions are made (supralateral for the
patella and medial and lateral for the patellar tendon). A
thorough diagnostic arthroscopic examination is then
done. Removal of loose bodies and other necessary
intraarticular procedures are done first (meniscus, plica).
The focal cartilage lesion is then measured using a stand-
ard 4-mm arthroscopic probe and ICRS graded [30, 31].
Then either arthroscopic debridement (AD) or autolo-
gous chondrocyte implantation (ACI) is done, depending
on randomization.
Autologous chondrocyte implantation
ACI is a three stage procedure taking place at Akershus
University Hospital and Oslo University Hospital (Ex-
Vivo Laboratory) over a two week period.
Stage 1: Debridement and cartilage harvest Stage 1
includes a diagnostic arthroscopy with full inspection of
the knee joint to ensure the inclusion criteria are fulfilled.Loose bodies are removed, any meniscal pathology is ad-
dressed. Inflamed synovium is debrided. The lesion is sta-
bilized by debridement around the edges and down to the
subchondral bone using a ring curette, but not through it,
as described above. Cartilage biopsy is then taken from
the non-weightbearing area of the medial aspect of the
femoral notch. If this area does not contain enough
healthy cartilage, the secondary donor site will be the
non-weight bearing aspect of the lateral femoral condyle.
Complications or donor site morbidity following arthro-
scopic harvesting of cartilage in this manner has not been
described [27].
Stage 2: Chondrocyte growth in ex vivo laboratory
Rikshospitalet, Oslo University Hospital The har-
vested cartilage is transported to the cell culture labora-
tory in a sterile tube containing 0.9 % NaCl. The cells
undergo mechanical mincing and antibiotic washing,
and isolation of the chondrocytes by overnight collage-
nase digestion. The chondrocytes are then cultured for
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million cells/ml. The cells are then transported back to
the orthopaedic department on the day of the
implantation.
Stage 3: Implantation of chondrocytes two weeks
after initial arthroscopy The chondrocyte implantation
is performed under general or spinal anaesthesia, and a
tourniquet inflated to 300 mmHg to achieve a blood-less
field is applied to the upper thigh. A mini-open arthrot-
omy (medial or lateral depending of the location of the
lesion) is performed and the lesion is assessed. The le-
sion is curetted down to subchondral bone, but care is
taken to avoid bleeding. The surrounding cartilage is
debrided to healthy tissue, exposing the lesion to bare
bone. The lesion is measured and a template of sterile
aluminium foil is used to model the exact shape of the
lesion, overcorrecting with 1–2 mm.
The template is then used to cut out a matching piece
of collagen sheet (ChondroGide® (Geistlich Pharma,
Switzerland)) which is used to contain the cells in the
defect. The flap is sutured to the lesion with 6.0 resorba-
ble stitches and sealed with fibrin glue, leaving and
opening at the upper part for injection of the cells. Sa-
line is injected to the cavity to check for leakage, then
aspirated before the cells are slowly injected using a soft
catheter. The last opening is then closed with a last
stitch and fibrin glue. The knee is then closed in the
standard manner, taking care to close the capsule with
subcutaneous resorbable sutures, before closing the skin
incision with nylon sutures.
Arthroscopic debridement
The AD group will be subjected to a diagnostic arthros-
copy with a full inspection of the knee joint to ensure
the inclusion criteria are fulfilled. Lose bodies are re-
moved, any meniscal pathology is addressed. Inflamed
synovium is debrided. The lesion is stabilized by de-
bridement around the edges and down to the subchon-
dral bone using a ring curette, but not through it.
Microfracture or any other cartilage treatment will not
be performed.
No intra-articular local anesthetics will be used due to
the possible harmful effect on cartilage [33–35]. All the
operating surgeons will receive proper training in the
operative procedure before study start.
Post-operative management
The two treatment groups will receive identical postop-
erative care. The patients are usually admitted to the
hospital for up to 4 days. No intravenous prophylactic
antibiotics is given, anti-thrombotic prophylaxis is given
only when there is a risk of thromboembolic disease
(such as previous deep vein thrombosis or pulmonaryembolus, protein C or S deficiency, Leiden V mutation
and use of contraceptive pills). All patients will be given
a sick leave up to 2 weeks after the operation.
If a patient experiences complications during treat-
ment such as wound infections, catching or locking etc.
the patient will receive medical attention and follow-up
according to the problem.
Rehabilitation protocol
The two treatment groups will receive identical rehabilita-
tion protocol according to a modification of Wondrasch
et al. [23]. The patients are admitted to the hospital for 2–
4 days. The patients are seen by a physiotherapist and the
surgeon day 1 after surgery to be instructed in range of
motion exercises and restrictions according to Phase 1.
The patient is seen within two weeks by a local physio-
therapist who has received information about the rehabili-
tation program, and who will follow the patient through
the program, supervised by the Project Physiotherapist.
The rehabilitation program is an active rehabilitation
and education program divided into 3 phases: accommo-
dation (1), rehabilitation (2) and return to activity (3)
(Table 2). During the rehabilitation program the physical
therapist focuses on explaining why the exercises are im-
portant and how the exercises should be performed and
adjusted based on pain response and other symptoms.
The rehabilitation program consists primarily of cardio-
vascular and knee/hip progressive resistance and neuro-
muscular training, including balance and plyometric
exercises. The local physical therapist receives informa-
tion about the rehabilitation program, including what
kind of exercises the patients should perform.
To monitor the adherence to the rehabilitation program,
all patients are asked to use training diaries to provide in-
formation about frequency, type of exercise, load progres-
sion and number of repetitions. In addition, the patients
are asked to respond every second week to an online sur-
vey, with the questions; 1. Have you been to a supervised
physical therapy session during the last two weeks?, 2.
How many physical therapy sessions did you attend during
the last two weeks? 3. What kind of training/exercises have
you performed during the physical therapy sessions? and 4.
What kind of activities have you performed during the last
two weeks? All questions are followed by several prede-
fined answers (closed answers), but also open answers are
included to make comments if required. The online survey
will continue as long as the patient is under the care of a
physiotherapist, while the training diary will be continued
to the end of the project (24 months) to estimate the
amount of home exercise performed by the patient.
Phase 1 - Accomodation
Inpatient rehabilitation consists of placing the leg in a
Continuous Passive Motion (CPM) machine within the
Table 2 Rehabilitation protocol (identical for both groups)
Rehabilitation phases Physiotherapy and activities Objectives Criteria for progression to next phase
Phase1: Accomodation Education/coaching Reduce pain and swelling No pain & swelling during activities of daily
living (ADL)
Ice, elevation and compression Normalize range of motion Flexion 90°
Isometric exercises Regain quadriceps control Normalized quadriceps activity while walking
(clinical evaluation by the physical therapist)
Range of motion
Gait training (no weight-bearing
for two weeks)
Phase2: Rehabilitation Stationary bike cycling Recovery of full range of motion Full range of motion
Progressive knee and hip
resistance training
Normalize muscle strength No pain or swelling during and after training
sessions
Neuromuscular training Dynamic joint stability during ADL Equally distributed weight on the lower limbs
during weight-bearing exercises with no shift
of the trunk (visually assessed by the physical
therapist)
Ability to stand on 1 limb on a flat surface for
at lest 10 s
Phase 3: Return to activity Knee and hip resistance training Recovery of strength and
neuromuscular control
Return to sport based on individual assessment
Neuromuscular training Return to activity/sport
Cardiovascular training
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achieve 30–70° day 1 after surgery. The patients should
use the machine for 6–8 h every 24 h. The physical ther-
apist instructs the patients in exercises such as active
dorsiflexion/ plantar flexion of the ankle to encourage
lower extremity circulation and isometric contraction of
the quadriceps, hamstrings, and gluteal musculature to
maintain muscle tone and minimize muscle loss. This
also includes abduction exercises for the hip. The pa-
tients remain non-weight bearing for two weeks, but are
allowed touch-down weight-bearing (the foot or toes
may touch the floor, but not support any weight)
through the affected limb using crutches.
When discharged from the hospital, the patients are en-
couraged to continue range of motion exercises; flexion/
extension of the knee 500 repetitions three times a day. In
this phase, 2 to 3 supervised physical therapy sessions are
scheduled for each patient. Interventions such as ice, com-
pression, electrical muscle stimulation, muscle activation
of the quadriceps, hamstrings, gastrocnemius and gluteal
muscles and gait training is included. Swimming is
allowed when the wounds are healed.
After two weeks, protected weight-bearing is carefully
introduced within the pain threshold and gradually in-
creased up to full weight-bearing (continues into phase 2).
Crutches are used until the patient walks normal without
limping.
Phase 2 - Rehabilitation
The patients attends 2 or more supervised physical ther-
apy sessions per week, in addition they perform 1 to 2unsupervised training sessions per week. Cardiovascular
training on a stationary bike and progressive knee and
hip resistance training and neuromuscular training are
performed in this phase. All strengthening exercises are
performed with both the injured and uninjured limbs.
When full weight-bearing is achieved, long distance
walking with increasing distances is encouraged and
cross-country skiing can be allowed.
Phase 3 - Return to activity/sport
This phase is individualized according to the goals for
each patient. The patients attend 1 or more supervised
sessions per week, in addition they perform resistance
training for a minimum of 2 and a maximum of 4 ses-
sions per week. Cardiovascular and neuromuscular train-
ing can be performed daily. Where a return to sport is
planned, it is important that sport-specific activities are
included as functional progressions within the rehabilita-
tion program.
Outcome measures (dependent variables)
Demographics
Demographics to be collected at inclusion is age, gender,
height (cm), weight (kg), BMI, injury mechanism (if
any), previous medical history, current medication,
smoking, social status, work status and nationality.
Primary endpoint
The Knee Injury and Osteoarthritis Outcome Score
(KOOS) is a patient reported outcome measure validated
to use in cartilage research studies and will enable
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five domains; pain, symptoms, activity of daily living,
sport and recreational function and knee-related quality
of life [36]. KOOS knee-related quality of life (QoL) sub-
score is the primary endpoint, where the primary aim is
the difference in KOOS QoL subscore in the ACI group
compared to the AD group at 2 years follow up. There
will not be any interim analysis before 2 years follow up.
Secondary endpoints
A combination of self-explanatory questionnaires, clin-
ical parameters, clinical hop tests and radiographs and
Magnetic Resonance Imaging (MRI) will be used as sec-
ondary endpoints. The secondary aims will be the differ-
ence between the two treatment groups and within the
group at predefined times as described below. The sec-
ondary aims are:
 KOOS score: all subscores except the knee-related
QoL subscore which is the primary aim.
 Tegner score; To evaluate the level of physical
activity.
 Lysholm score; A condition-specific outcome score
containing eight domains; limp, locking, pain, stair-
climbing, use of support, instability, swelling and
squatting.
 EQ-5D; A generic measure of health status that
provides a simple descriptive profile used in the clinical
evaluation of health care. EQ-5D is also widely used by
clinical researchers and recommended for use in cost-
effectiveness analyses by the Washington Panel on Cost
Effectiveness in Health and Medicine [37] and by the
International Society for Pharmacoeconomics and
Outcomes Research (ISPOR) task force on good
clinical practices: Randomized Clinical Trial-Cost-
Effectiveness Analysis (RCT-CEA) [38].
 Visual analogue scale (VAS); A visual analogue scale
for pain, where 0 represents no pain and 10
represents the worst pain imaginable.
 Range of motion (ROM) will be measured with a
goniometer
 Costs; resource use related to the intervention,
medication, rehabilitation, use of health care services
and production loss.
 The patients will also provide information about work
(return to work) physical activity and return to sport.
All outcome questionnaires will be completed by the
patients before surgery (pre-operative or baseline values)
and at the designated research follow-up appointments
at 3 (±2 weeks), 6 (±4 weeks), 12 (±6 weeks), and 24
(±8 weeks) months.
At 24 months follow up, there will be 3 additional ele-
ments consisting of: Standing x-rays to evaluate any development of
osteoarthritis.
 Magnetic Resonance Imaging (MRI); assessing the
quality of the cartilage tissue, using a specific cartilage
MRI technique, to assess the healing of the defect.
 A hop test, validated and described previously by
Noyes, to assess clinical function [39].
We will also invite patients to attend a 5 year and
10 year follow up appointment. During these late con-
trols, all the primary and secondary outcomes will be
assessed for as described above.Hypothesis
Null hypothesis: There is no difference in KOOS sub-
score quality of life following ACI or AD treatment of a
symptomatic cartilage defect (>2 cm2) in the weight
bearing area of the knee 2 years after surgery.
The alternative hypothesis claims that differences be-
tween ACI and AD in KOOS quality of life subscore exist.Statistical analysis
Demographic and clinical characteristics will be pre-
sented as means and standard deviations (SD) or fre-
quencies and percentages, as appropriate. The normality
of continuous data will be assessed by examining the
histograms. If necessary, a suitable transformation will
be considered to symmetrize the data.
Due to along follow-up period with 5 (7) measurement
points, repeated observations will be available for each
patient. A mixed model correctly adjusting for intra-
patient correlations will be used to assess the trend in
primary and secondary end-points. The model will con-
tain random effects for intercepts and slopes, if signifi-
cant. Fixed effects for time (likely non-linear) and group
will be included together with the interaction between
the two. The interaction will quantify possible differ-
ences between arms regarding time profiles and serve as
an omnibus test. For continuous end-points, linear
mixed model will be estimated, while generalized linear
model will be fitted to dichotomous end-points. Relevant
pairwise comparisons will be performed by deriving indi-
vidual time point contrasts within each study arm. The
results will be presented as estimated means of odds ra-
tios together with the corresponding 95 % confidence in-
tervals (CI) and p-values. The estimates will further be
adjusted for possible confounders such as age of the pa-
tient and severity of the cartilage lesion in the multivari-
ate regression models.
The results with p-values below 0.05 will be consid-
ered statistically significant. Two-sided tests will be used.
The data analysis will be conducted using SPSS v.22
(SPSS Inc, Chicago, Illinois) and SAS v 9.4.
Randsborg et al. BMC Musculoskeletal Disorders  (2016) 17:117 Page 8 of 9Sample size
It has previously been shown that a change in subscore
of 8–10 of KOOS QoL (quality of life) is clinically sig-
nificant [40, 41]. Therefore, for power analysis a differ-
ence in change of 10 between two treatment groups was
assumed. A SD for change of 15 was used [42]. With the
power of 80 % and significance level of 5 % the esti-
mated minimum number of patients was 37 in each
group. By adding 10 % due to loss during follow-up, we
therefore plan to include a total of 82 patients.
Risk assessment
Some patients may find it unpleasant when asked about
demographic information. The treatment of choice in
this patient population is not established, but standard
clinical care include both arthroscopic debridement
(AD) and autologous chondrocyte implantation (ACI).
There are no additional risks of this study other than the
potential risks of standard clinical practice.
Potential risk of AD is rare with a frequency < 1 % and
include infection, deep vein thrombosis (DVT), arthral-
gia, headache, joint effusion/swelling, nasopharyngitis.
Potential risk of ACI is rare, but slightly higher than for
AD, as this treatment involves a second operation with a
mini-opening of the knee. Four major complications re-
quiring surgery following ACI have been identified [43]:
– Malfusion of the repair tissue to the bed of the
lesion (3.8 %)
– Delamination of healthy cartilage near lesion (2.8 %)
– Hyperthrophy of the repair tissue (>2 %)
– Insufficient degenerative tissue (>2 %)
Other complications are rare and occurs in < 1 % of
patients, such as wound break down, infection, DVT and
joint stiffness.
Both treatments have a risk of failure, meaning that
the pain and stiffness in the knee does not improve des-
pite surgery, and further surgery might be required.
Discussion
The treatment of isolated full thickness cartilage lesions
of the knee is difficult, and various surgical techniques
are available. Since its introduction in the late 1980s
Autologous Chondrocyte Implantation has become a
recognize method for larger lesions. This method is
costly and demands patience and strict compliance from
the patients. The results have been promising, but the
method has not been directly compared to physiother-
apy. This study will therefore answer pertinent questions
regarding the added benefit of ACI compared to physical
rehabilitation alone. The results will help surgeons im-
prove clinical outcome after cartilage injuries of the
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